Synovus price target raised to $41 from $38 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Synovus to $41 from $38 and keeps an Equal Weight rating on the shares. An operating EPS beat driven by higher revenues from securities repositioning and better capital markets sets the stage for stronger growth in 2025, though higher expenses are a partial offset, the analyst tells investors in a post-earnings note.